how does treatment with ide-cel impact quality of life in rrmm?
Published 9 months ago • 78 plays • Length 3:58Download video MP4
Download video MP3
Similar videos
-
6:52
health-related quality of life in rrmm patients treated with ide-cel vs belantamab mafodotin
-
2:07
the clinical outcomes and qol after treatment with ide-cel in older patients with myeloma
-
3:54
enhanced health-related quality of life (hrqol) with ide-cel treatment in patients with refracto...
-
1:58
karmma study shows improved qol in patients with r/r multiple myeloma treated with ide-cel
-
4:34
what is ide-cel and how can it benefit myeloma patients?
-
5:20
advancements in myeloma treatment: real world outcomes and quality of life | doris hansen, md
-
2:08
impact of bridging therapy on the outcomes of patients with r/r myeloma treated with ide-cel
-
14:34
real-world outcomes for patients treated with ide-cel after having received a bcma-targeted therapy
-
26:22
acquired immunodeficiency disease part1
-
13:19
using the immune system to fight multiple myeloma
-
20:51
myeloma patients are having longer remissions with this game changing treatment! | the patient story
-
1:43
ide-cel therapy for multiple myeloma with renal impairment
-
2:30
impact of bridging therapy on the outcomes of patients with r/r myeloma treated with ide-cel
-
10:18
ide-cel; bb2121, a bcma-targeted car t-cell therapy, in patients with rrmm: initial karmma results
-
6:34
ide-cel in r/r myeloma: patient-reported outcomes and resistance
-
1:08
the impact of extramedullary multiple myeloma on outcomes with ide-cel
-
3:41
characteristics of neurotoxicity associated with ide-cel in pts with rrmm in phase ii karmma
-
2:41
the impact of sustained undetectable mrd on survival in patients with myeloma treated with ide-cel
-
1:28
real-world experience: ide-cel for r/r multiple myeloma
-
25:25
advances in treating multiple myeloma help extend quality of life for patients
-
9:40
comparing health related quality of life in tce rrmm: ide-cel vs. standard regimens | asco 2023
-
2:08
safety, efficacy and tolerability of ide-cel in the real-world